Cytovant Sciences Co., Ltd. is a clinical-stage biopharmaceutical company with a mission to develop novel cellular therapeutics uniquely suited to Asian patients. Launched in April 2019 by ROIVANT SCIENCES, the company is headquartered in Hong Kong with offices in Shanghai and Beijing, China. While focusing on research and development programs of cell therapy, Cytovant aims to address prevalent diseases in Asia. The company's approach, TCR-T, targets solid tumors, representing a substantial market opportunity, especially in Asia where populations have unique immunological characteristics and specific disease burdens not well addressed by current therapies.
To accelerate the delivery of new cell therapies to Asian patients, Cytovant has entered into a multi-program license and collaboration agreement with Medigene AG, a German clinical-stage biotechnology company. Their most advanced R&D program, CVT-TCR-01, is a potential best-in-class NY-ESO-1-targeted TCR-T therapy for treating multiple solid tumor types. The company raised $23.50M in a Venture Round investment on 03 April 2020, with participation from Mirae Asset Venture Investment, POSCO Venture Capital, Smilegate Investment, and BNH.
Zelluna Immunotherapy